ANDA Review
ANDA review is the regulatory evaluation stage where the submitted generic drug application is checked for quality, labeling, product sameness, and approval readiness. This review gives an Abbreviated New Drug Application its decision stage because the regulator must judge whether the proposed generic medicine can be approved based on an already approved reference drug. Because the application is abbreviated, the review does not examine original safety and effectiveness evidence from the beginning — it focuses on whether the submitted generic drug meets the sameness and quality standards set by the already approved reference medicine.
Regulatory Evaluation Stage
ANDA review begins after the application has been filed and accepted for examination. At this stage, the regulator studies the submitted information to decide whether the proposed generic drug meets the standards needed for approval.
Product Sameness Check
The review checks whether the proposed generic drug matches the approved reference medicine in required areas such as active ingredient, strength, dosage form, and route of administration. This helps confirm that the product belongs in the generic drug approval pathway.
Quality Evaluation
Quality evaluation focuses on whether the medicine can be made consistently and safely. The regulator examines quality-related information to confirm that the proposed generic drug can meet acceptable standards before it is allowed for marketing.
Labeling Evaluation
Labeling evaluation checks whether the proposed generic drug information is suitable for patients, pharmacists, and healthcare professionals. The label should carry proper directions, dosage details, warnings, precautions, and safety information connected with the approved reference medicine.
Equivalence Evidence Check
The regulator also reviews evidence showing whether the proposed generic medicine is comparable to the reference drug. This may include performance-related information that helps decide whether the generic product can be accepted as an alternative version.
Regulatory Questions
During ANDA review, the regulator may ask questions when information is missing, unclear, inconsistent, or not strong enough. These questions allow the applicant to correct or explain issues before the application moves toward a final decision.
Approval Decision
The review ends with a regulatory decision. If the submitted evidence supports quality, sameness, labeling, and required comparison with the approved reference drug, the generic medicine may receive approval for marketing.
ANDA review decides whether the filed generic drug request is strong enough to move from application to approval. The main ANDA full form article explains the acronym before this review stage begins.